DeuterOncology, a Liege, Belgium-based clinical-stage drug development company, raised €5.65M in Series A funding.
The round was led by Newton Biocapital, Noshaq and Investsud Tech.
The company intends to use the funds to start the phase I clinical study for its lead product DO-2, an improved MET kinase inhibitor currently being developed as a potential best-in-class targeted therapy for lung cancer.
Led by Timothy Perera, Founder and CEO, DeuterOncology is a clinical-stage biotech company focusing on the development of a dual MET and RAS pathway inhibitor for targeted cancer therapies. The company has generated preclinical validation of its lead candidate DO-2, a novel, selective, brain penetrant deuterated MET and RAS pathway inhibitor that was inlicensed (worldwide rights outside of greater China) from OCTIMET Oncology NV and originally licensed in 2017 from Janssen Pharmaceutica. DeuterOncology has initiated a phase I clinical study to validate DO-2 as a best-in-class MET kinase inhibitor as suggested by the strong preclinical data package.
FinSMEs
19/01/2022